Figure 1.

A 61-year-old patient, first diagnosed in 08/2015 with histological diagnosis of adenocarcinoma of prostate, Gleason score 5 + 4, was referred for radioligand therapy due to disease progression after treatment with firmagon, docetaxel, lucrin, external beam radiation therapy and 1 cycle of cisplatin/cabazitaxel. His lab values showed PSA < 0.01 µg/L, CgA 767 ng/mL, NSE 277 µg/L. PSMA PET/CT (Left) was performed to assess the feasibility of performing Lu-177 PSMA therapy. Because of his low PSA level and elevated tumor markers for neuroendocrine differentiation, this patient was also examined with Ga-68 DOTATOC PET/CT (Right). The maximum projection intensity images showed more somatostatin receptor positive lesions as compared to PSMA avid lesions. Images provided by Rachelle Steyn from University of Cape Town, South Africa.